CD47 and medulloblastoma: The CD47 biological impact in medulloblastoma was investigated by Gholamin et al., that reported high expression levels of CD47 in medulloblastoma datasets and further showed in mice models that targeting CD47 by the monoclonal antibody magrolimab resulted in enhanced phagocytic capacity and tackled tumor primary and metastatic capacity in a model of Group 3 medulloblastoma (57).